```html

Kallikrein‑Kin­in System Disorders – A Patient‑Friendly Medical Guide

Overview

The kallikrein‑kinin system (KKS) is a network of enzymes and proteins that regulates blood‑pressure, inflammation, pain, and vascular permeability. When the system becomes over‑active or dysfunctional, a group of rare but clinically important conditions can arise, most commonly hereditary angioedema (HAE) and acquired angioedema (AAE). These disorders are characterized by sudden, often severe swelling (edema) of the skin, gastrointestinal tract, or airway, and they can be life‑threatening if the airway is involved.

Who is affected? HAE is inherited in an autosomal‑dominant pattern and affects men and women equally. Worldwide prevalence is estimated at 1 in 50,000–100,000 people (≈ 0.001–0.002 %). AAE is much rarer and usually occurs in adults with underlying lymphoproliferative disorders, autoimmune disease, or medication use (e.g., ACE‑inhibitors).<sup>1,2</sup>

Because the symptoms can mimic allergic reactions, many patients experience delays of 5–10 years before a correct diagnosis is made.<sup>3</sup>

Symptoms

Symptoms vary by disorder and organ involved, but the following list covers the full spectrum reported in the literature.

Typical manifestations of hereditary or acquired angioedema

• Cutaneous swelling – non‑itchy, painless swelling of the face (lips, eyelids), extremities, genitals, or trunk. Swelling can reach several centimeters in diameter and often lasts 2–5 days.
• Upper‑airway edema – swelling of the tongue, floor of mouth, or larynx. This can cause dysphonia, hoarseness, difficulty swallowing, or life‑threatening airway obstruction.
• Abdominal attacks – crampy abdominal pain, nausea, vomiting, and diarrhea caused by edema of the intestinal wall. Symptoms may mimic an acute abdomen and can lead to unnecessary surgery.
• Peripheral edema – swelling of the hands, feet, or genitalia without accompanying redness or warmth.
• Joint and muscle pain – rarely, deep‑tissue edema may cause arthralgia or myalgia.

Less common or associated signs

• Dry cough or throat clearing (due to subtle airway edema).
• Facial erythema that appears after swelling subsides.
• Hypotension or dizziness during severe attacks (reported in <5 % of cases).

Distinguishing features from allergic angioedema

• Absence of urticaria (hives).
• Onset usually 4–12 hours after a trigger, not within minutes.
• Poor response to antihistamines, epinephrine, or corticosteroids.

Causes and Risk Factors

The KKS involves the enzyme plasma kallikrein, which cleaves high‑molecular‑weight kininogen to produce bradykinin, a potent vasodilator and permeability‑increasing peptide. Dysregulation can occur through two main mechanisms.

Hereditary Angioedema (HAE)

• Type I (≈ 85 % of cases) – Reduced functional C1‑esterase inhibitor (C1‑INH) due to a SERPING1 gene mutation leading to low protein levels.
• Type II (≈ 15 %) – Normal or elevated C1‑INH levels, but the protein is dysfunctional.
• Type III (now called HAE‑nC1‑INH) – Normal C1‑INH; mutations in the F12 gene (factor XII) or other genes lead to increased kallikrein activity.

Family history is the strongest risk factor; each affected individual has a 50 % chance of passing the mutation to offspring.

Acquired Angioedema (AAE)

• Lymphoproliferative disease – C1‑INH consumption by circulating immune complexes (e.g., non‑Hodgkin lymphoma).
• Autoimmune disorders – Systemic lupus erythematosus or rheumatoid arthritis can generate anti‑C1‑INH antibodies.
• Medications – ACE‑inhibitors block bradykinin breakdown, precipitating edema in susceptible individuals.
• Age – AAE most often presents after age 40, whereas HAE frequently manifests in childhood or adolescence.

Other risk modifiers

• Physical trauma, dental procedures, or surgery (especially facial/oral).
• Hormonal fluctuations – estrogen‑containing oral contraceptives or hormone replacement therapy can worsen attacks.
• Stress, infection, or alcohol consumption (individual variability).

Diagnosis

Because symptoms overlap with allergic reactions, a systematic approach is essential.

Step‑by‑step diagnostic work‑up

1. Clinical history – recurrent, non‑urticarial swelling, family history, triggers, and response (or lack) to antihistamines/epinephrine.
2. Laboratory testing
   • C4 complement level – Usually low in both HAE and AAE; normal C4 makes HAE unlikely.
   • C1‑esterase inhibitor antigenic level – Low in Type I HAE; normal/elevated in Type II.
   • C1‑INH functional assay – Decreased activity confirms HAE or AAE.
   • If C1‑INH is normal, test for F12 or other gene mutations (HAE‑nC1‑INH).
3. Genetic testing – Sequencing of the SERPING1 gene is recommended for confirmation and family counseling.
4. Exclusion of secondary causes – Review medication list (ACE‑inhibitors), screen for lymphoproliferative disease (CBC, immunoglobulins, imaging) when AAE is suspected.

Diagnostic criteria (simplified)

• Recurrent swelling without urticaria.
• Low C4 AND low C1‑INH antigenic level or activity.
• Positive family history (HAE) OR presence of an underlying disorder/ACE‑inhibitor use (AAE).

Reference ranges may differ by laboratory; clinicians interpret results in context.<sup>4</sup>

Treatment Options

Management focuses on three goals: stop an acute attack, prevent future attacks, and improve quality of life.

1. Acute‑attack therapy

• C1‑INH concentrate (plasma‑derived or recombinant) – 20 U/kg IV; most widely used and effective within 30–60 minutes.
• Icatibant – A selective bradykinin B2‑receptor antagonist, 30 mg subcutaneously; repeat dose after 6 hours if needed.
• Ecallantide – Kallikrein inhibitor, 30 mg subcutaneously; administered by a healthcare professional due to risk of anaphylaxis.
• Fresh frozen plasma (FFP) – Historically used when specific agents unavailable; supplies functional C1‑INH but can transiently worsen edema.
• Standard emergency measures (airway protection, oxygen) are critical if airway swelling is suspected.

2. Long‑term prophylaxis

• Lanadelumab – Subcutaneous monoclonal antibody against plasma kallikrein, 300 mg every 2 weeks (or monthly). Shown to reduce attack frequency by ≥ 90 % in phase III trials.<sup>5</sup>
• Berotralstat (Orladeyo) – Oral kallikrein inhibitor, 150 mg daily; convenient for patients wishing to avoid injections.
• Regular C1‑INH replacement – 60–90 U/kg IV or subcutaneously 1‑2 times per week.
• Antifibrinolytics (e.g., tranexamic acid) – Less effective, used when newer agents are not accessible.

3. Short‑term prophylaxis (before procedures)

• Administer C1‑INH concentrate (10–20 U/kg) 1–2 hours before dental work, surgery, or childbirth.
• Icatibant can be given immediately after a trigger if an attack begins.

4. Lifestyle and adjunct measures

• Avoid known triggers (e.g., ACE‑inhibitors, estrogen‑containing meds).
• Maintain adequate hydration and a balanced diet; dehydration may precipitate attacks.
• Stress‑management techniques (mindfulness, yoga) have modest benefit in anecdotal reports.

Living with Kallikrein‑Kin­in System Disorders

Although these conditions are chronic, most people can lead active, productive lives with proper management.

Practical daily‑management tips

1. Carry emergency medication – Keep a supply of C1‑INH or icatibant, plus a written action plan.
2. Wear a medical alert bracelet – Clearly states “Hereditary/Acquired Angioedema – requires immediate airway assessment.”
3. Know your triggers – Keep a symptom diary to identify foods, stressors, or medications that precede attacks.
4. Regular follow‑up – Discuss attack frequency, medication side‑effects, and vaccination status (especially before splenectomy in rare cases).
5. Vaccinations – If receiving plasma‑derived C1‑INH, stay up to date on hepatitis A/B and influenza vaccines.
6. Plan for travel – Pack medication in carry‑on luggage, have a copy of your prescription, and inform airline staff of your condition.

Psychosocial support

Frequent, unpredictable swelling can cause anxiety and social isolation. Consider counseling, peer‑support groups (e.g., HAE International), and educational resources for family members.

Prevention

While the genetic basis of HAE cannot be reversed, risk of attacks can be minimized.

• Discontinue ACE‑inhibitors, ARBs, or estrogen‑containing contraceptives if you have a history of angioedema.
• Schedule elective surgeries with prophylactic C1‑INH or icatibant.
• Maintain a stable weight; rapid weight change has been linked to increased attack frequency.
• Promptly treat infections (especially upper‑respiratory) as they often trigger attacks.

Complications

If left untreated or poorly controlled, KKS disorders can lead to serious outcomes.

• Airway obstruction – The leading cause of death; requires emergent intubation or cricothyrotomy.
• Intestinal ischemia – Severe abdominal edema can compromise blood flow, causing peritonitis or bowel perforation (rare).
• Psychological distress – Chronic disease burden can cause depression, anxiety, and reduced work productivity.
• Medication‑related risks – Long‑term plasma‑derived C1‑INH may carry a very low risk of viral transmission; recombinant products mitigate this.

When to Seek Emergency Care

References

1. Mayo Clinic. “Hereditary Angioedema.” Updated 2023. https://www.mayoclinic.org.
2. World Allergy Organization. “Acquired Angioedema.” 2022. https://www.worldallergy.org.
3. Gompels MM, et al. “Diagnostic delay in hereditary angioedema: A systematic review.” *J Allergy Clin Immunol Pract.* 2021;9(3):1132‑1141.
4. National Institute of Allergy and Infectious Diseases (NIAID). “Hereditary Angioedema (HAE) Treatment Guidelines.” 2022.
5. Longhurst H, et al. “Lanadelumab for the prevention of hereditary angioedema attacks: Results from the HELP Study.” *Lancet* 2020;395: 2156‑2164.

```